ContractMinerva Neurosciences, Inc. • May 12th, 2021 • Pharmaceutical preparations
Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed.
April 27, 2021 Re:Supplemental Retention Benefit Dear __________:Minerva Neurosciences, Inc. • May 12th, 2021 • Pharmaceutical preparations
You will recall that last year the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) adopted a retention program for certain of its key employees, pursuant to which the Company provided certain cash and equity incentives designed to retain employees (the “Retention Program”).
ContractMinerva Neurosciences, Inc. • May 12th, 2021 • Pharmaceutical preparations
Certain identified information identified with brackets (“[•••]”) has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed.
